Healthcare · Biotechnology
Price
$3.60
Market Cap
$11.1M
Employees
4
Beta
1.61
Avg Volume
70,977
CEO
Quang X. Pham
Business Description
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Business History
Price Overview
Price at report time · Jul 3, 6:45am (0m ago)
$3.60
Change · Jul 3
+0.43 (+13.56%)
Day Range
$3.09 – $3.89
52-Week Range
$2.55 – $14.64
50-Day MA
$4.65
200-Day MA
$8.00
Volume
106,518.00
Right now · live
loading…
Real-time — the change above is the move since the report (over 0m).
Analyst Price Targets
Low
$32.00
Consensus
$32.00
High
$32.00
(1 analysts)
Share Structure
Outstanding
3,078,247.00
Float
2,435,313.00
Free Float
79.1%
Normal free float
— 79.1% of shares trade freely, ~20.9% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Small absolute float (2.4M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.54
Stock Price: $3.60
EPS (Diluted): -6.64
EPS (Diluted): -6.64
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
4.94
Stock Price: $3.60
Total Equity: $2.74M
Shares: 1,993,757
Total Equity: $2.74M
Shares: 1,993,757
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.74
Market Cap: $11.08M
Total Debt: $0.00
Cash: $4.01M
EBITDA: -$13.23M
Total Debt: $0.00
Cash: $4.01M
EBITDA: -$13.23M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$9.5M
Market Cap: $11.08M
Total Debt: $0.00
Cash: $4.01M
Total Debt: $0.00
Cash: $4.01M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $3.60
Revenue: $0.00
Shares: 1,993,757
Revenue: $0.00
Shares: 1,993,757
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$13.46M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$13.24M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-411.0%
Net Income: -$13.24M
Total Equity: $2.74M
Total Equity: $2.74M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-670.4%
Operating Income: -$13.46M
Tax Rate: 0.0%
Equity: $2.74M
Total Debt: $0.00
Cash: $4.01M
Tax Rate: 0.0%
Equity: $2.74M
Total Debt: $0.00
Cash: $4.01M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.72
Current Assets: $4.32M
Current Liabilities: $1.59M
Current Liabilities: $1.59M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $2.74M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $2.74M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 1,993,757
Shares: 1,993,757
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$1.37
Total Equity: $2.74M
Shares: 1,993,757
Shares: 1,993,757
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-6.32
Operating CF: -$12.60M
CapEx: -$5,104
Shares: 1,993,757
CapEx: -$5,104
Shares: 1,993,757
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $3.60
Stock Price: $3.60
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$13.24M
Net Income: -$13.24M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares CVKD against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 3, 2026 6:45am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | $1,266 | $0 | $0 | $0 |
| Gross Profit | $-1,266 | $0 | $0 | $0 |
| Operating Expenses | $2.7M | $7.6M | $11.0M | $13.5M |
| Operating Income | -$2.7M | -$7.6M | -$11.0M | -$13.5M |
| Net Income | -$6.7M | -$8.4M | -$10.7M | -$13.2M |
| EBITDA | -$6.6M | -$8.3M | -$10.6M | -$13.2M |
| EPS | $-8.66 | $-9.63 | $-8.73 | $-6.64 |
| EPS (Diluted) | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 3, 2026 6:45am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash & Equivalents | $32,586 | $8.4M | $10.0M | $4.0M |
| Total Current Assets | $727,596 | $8.5M | $10.1M | $4.3M |
| Total Assets | $778,174 | $8.5M | $10.1M | $4.3M |
| Current Liabilities | $1.3M | $826,875 | $2.7M | $1.6M |
| Long-Term Debt | $553,340 | $0 | $0 | $0 |
| Total Liabilities | $6.3M | $826,875 | $2.7M | $1.6M |
| Total Equity | -$5.6M | $7.7M | $7.4M | $2.7M |
| Retained Earnings | -$6.7M | -$15.1M | -$25.7M | -$39.0M |
Cash Flow (Annual)
Last updated: Jul 3, 2026 6:45am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -$1.2M | -$3.5M | -$7.4M | -$12.6M |
| Capital Expenditure | $0 | $-3,254 | $-6,537 | $-5,104 |
| Free Cash Flow | -$1.2M | -$3.5M | -$7.4M | -$12.6M |
| Acquisitions (net) | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — |
| Dividends Paid | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $-291,883 |
| Net Change in Cash | $32,585 | $8.4M | $1.6M | -$6.0M |
Analyst Estimates (Annual)
Last updated: Jul 3, 2026 6:45am (just now)| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue | $0 |
$6.3M $6.3M – $6.3M
|
$16.8M $16.8M – $16.8M
|
$0 |
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$11.7M -$15.4M – -$8.0M
|
-$6.8M -$7.8M – -$5.8M
|
-$5.2M -$5.8M – -$4.6M
|
$17.0M $17.0M – $17.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 3, 2026 6:45am (just now)| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | — | — | — |
| Gross Profit Growth | +100.0% | — | — |
| Operating Income Growth | -182.5% | -43.6% | -22.8% |
| Net Income Growth | -24.5% | -27.5% | -24.3% |
| EBITDA Growth | -26.2% | -27.7% | -24.2% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-29 | Pham Quang X | S-Sale | 7,400.00 | $3.03 | $22,422 |
| 2026-06-25 | Pham Quang X | S-Sale | 2,127.00 | $3.00 | $6,381 |
| 2026-06-26 | Pham Quang X | S-Sale | 9,029.00 | $3.05 | $27,538 |
| 2026-06-22 | Pham Quang X | S-Sale | 9,167.00 | $3.55 | $32,543 |
| 2026-06-23 | Pham Quang X | S-Sale | 2,277.00 | $3.20 | $7,286 |
| 2026-06-16 | Pham Quang X | S-Sale | 3,613.00 | $3.18 | $11,489 |
| 2026-06-17 | Pham Quang X | S-Sale | 513.00 | $3.16 | $1,621 |
| 2026-06-11 | Pham Quang X | S-Sale | 1,462.00 | $4.12 | $6,023 |
| 2026-06-12 | Pham Quang X | S-Sale | 12,996.00 | $3.94 | $51,204 |
| 2026-06-15 | Pham Quang X | S-Sale | 3,666.00 | $3.58 | $13,124 |
| 2026-06-08 | Pham Quang X | S-Sale | 5,893.00 | $4.38 | $25,811 |
| 2026-06-09 | Pham Quang X | S-Sale | 12,992.00 | $4.06 | $52,748 |
| 2026-06-10 | Pham Quang X | S-Sale | 3,500.00 | $4.21 | $14,735 |
| 2026-06-03 | Pham Quang X | S-Sale | 2,323.00 | $4.26 | $9,896 |
| 2026-06-04 | Pham Quang X | S-Sale | 3,898.00 | $4.41 | $17,190 |
| 2026-06-05 | Pham Quang X | S-Sale | 2,064.00 | $4.42 | $9,123 |
| 2026-05-29 | Pham Quang X | S-Sale | 303.00 | $5.01 | $1,518 |
| 2026-06-02 | Pham Quang X | S-Sale | 349.00 | $4.46 | $1,557 |
| 2026-05-11 | Pham Quang X | S-Sale | 6,476.00 | $5.76 | $37,302 |
| 2026-05-12 | Pham Quang X | S-Sale | 3,298.00 | $5.28 | $17,413 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for CVKD — it's generated by the pipeline (
market-narrative step).
No community reviews yet for CVKD.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.373 · 697c9e64 · 2026-07-02 20:17:59